If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.85    0.005 (0.13%)
Bid:
3.60
Ask:
3.885
Spread: 0.285 (7.917%)
Market Cap: £24.02m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Total Voting Rights

16 Aug 2022 08:03

RNS Number : 0957W
Immupharma PLC
16 August 2022
 

RNS | 16 August 2022 

ImmuPharma plc

Total Voting Rights

ImmuPharma plc ("ImmuPharma" or "the Company"), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM.

Consequently, the Company's issued share capital now comprises, 327,403,115 Ordinary Shares with one voting right each and 284,984,933 deferred shares with no rights to vote. As the Company does not hold any shares in treasury, the total number of voting rights in the Company is also 327,403,115 and this figure of Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Ends

For further information, please contact:

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer & Chairman

+ 44 (0) 207 152 4080

Lisa Baderoon, Head of Investor Relations & Non-Executive Director

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 3550

 

 

+44 20 3650 3650

 

 

+44 (0) 1483 413500

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRSFIESIEESEEA
Date   Source Headline
10th Jul 20077:01 amRNSPivotal phase II/III trial
13th Jun 20072:00 pmRNSAGM and Board Update
1st May 20077:02 amRNSPreliminary Results
27th Apr 20074:02 pmRNSBoard Appointment
15th Feb 20077:01 amRNSAppointment of adviser
7th Feb 20077:01 amRNSBoard Changes
19th Jan 20078:57 amRNSTotal Voting Rights
5th Jan 20072:27 pmRNSIssue of Equity
27th Dec 20062:53 pmRNSTotal Voting Rights
21st Dec 20067:01 amRNSIssue of Equity
30th Oct 20067:01 amRNSFurther Phase II Data
17th Oct 20067:00 amRNSPhase II Data
2nd Oct 20067:01 amRNSFDA Meeting on Lupus
26th Sep 20067:01 amRNSInterim Results
1st Aug 20067:01 amRNSPreliminary Results
5th Jul 20067:00 amRNSStart of phase II trial
12th Jun 20065:04 pmRNSAccounting reference dates
10th May 20067:00 amRNSPhase 1 Lupus results
11th Apr 20067:00 amRNSResearch Grants
15th Feb 20061:56 pmRNSResult of EGM and Placing
24th Jan 20064:30 pmRNSSch 1 Update - ImmuPharma plc
23rd Jan 20064:27 pmRNSCirc re. ImmuPharma posted
30th Nov 20051:38 pmRNSInterim Results
27th May 20051:29 pmRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.